Results 311 to 320 of about 200,211 (350)
Some of the next articles are maybe not open access.
Osteolysis in Chronic Myeloid Leukemia
Tumori Journal, 1978Four patients affected by chronic myeloid leukemia who developed osteolytic lesions in the course of the disease are described. According to the literature, the appearance of these alterations seems to signify an unfavorable prognosis, since they occur slightly before or even at the same time as the blastic transformation of the disease.
G. Lambertenghi-Deliliers +3 more
openaire +4 more sources
Current Opinion in Oncology, 1992
Chronic myeloid leukemia is a clonal myeloproliferative disorder of a pluripotent stem cell with a specific cytogenetic abnormality, the Philadelphia chromosome, involving myeloid, erythroid, megakaryocytic, B lymphoid, and sometimes T lymphoid cells but not marrow fibroblasts.
openaire +5 more sources
Chronic myeloid leukemia is a clonal myeloproliferative disorder of a pluripotent stem cell with a specific cytogenetic abnormality, the Philadelphia chromosome, involving myeloid, erythroid, megakaryocytic, B lymphoid, and sometimes T lymphoid cells but not marrow fibroblasts.
openaire +5 more sources
2021
Chronic myeloid leukemia (CML) has evolved, on the basis of seminal research and transformative drug development, from a disease with a predictable short survival and limited curative potential, to a highly treatable and increasingly, functionally curable blood cancer. The genesis of prototypical small molecule inhibitors against a discrete genetic and
Manorama Bhargava, Manorama Bhargava
openaire +4 more sources
Chronic myeloid leukemia (CML) has evolved, on the basis of seminal research and transformative drug development, from a disease with a predictable short survival and limited curative potential, to a highly treatable and increasingly, functionally curable blood cancer. The genesis of prototypical small molecule inhibitors against a discrete genetic and
Manorama Bhargava, Manorama Bhargava
openaire +4 more sources
Autografting in chronic myeloid leukemia
Seminars in Hematology, 2003Autografting (or autologous stem cell transplant [ASCT]) followed by "rescue" with Philadelphia chromosome (Ph)-negative hematopoietic progenitor cells (HPC) remains a good procedure to guarantee prolonged survival for patients mobilized and autografted soon after diagnosis.
Angelo Michele Carella +2 more
openaire +3 more sources
The allometry of chronic myeloid leukemia
Journal of Theoretical Biology, 2009Chronic myeloid leukemia (CML) is an acquired neoplastic hematopoietic stem cell (HSC) disorder characterized by the expression of the BCR-ABL oncoprotein. This gene product is necessary and sufficient to explain the chronic phase of CML. The only known cause of CML is radiation exposure leading to a mutation of at least one HSC, although the vast ...
David Dingli +2 more
openaire +3 more sources
2016
The chronic myelogenous leukemia [CML] is a clonal disease of hematopoietic stem cells with unknown etiology. The incidence is around 2/100,000/year, the median age at diagnosis about 47 years. The course of CML is characterized by a chronic phase with few symptoms and good therapeutic response of about 4 to 5 years duration and by transition to a ...
openaire +3 more sources
The chronic myelogenous leukemia [CML] is a clonal disease of hematopoietic stem cells with unknown etiology. The incidence is around 2/100,000/year, the median age at diagnosis about 47 years. The course of CML is characterized by a chronic phase with few symptoms and good therapeutic response of about 4 to 5 years duration and by transition to a ...
openaire +3 more sources
The Biology of Chronic Myeloid Leukemia
New England Journal of Medicine, 1999Chronic myeloid leukemia (CML) is a clonal myeloproliferative expansion of transformed, primitive hematopoietic progenitor cells. It involves myeloid, monocytic, erythroid, megakaryocytic, B-lymphoid, and occasionally T-lymphoid lineages.1 CML was the first human disease in which a specific abnormality of the karyotype — the Philadelphia (Ph ...
Susan O'Brien +5 more
openaire +3 more sources
Curing Chronic Myeloid Leukemia
Current Hematologic Malignancy Reports, 2012The use of tyrosine kinase inhibitors (TKIs) targeted against the BCR-ABL1 oncoprotein has proven remarkably successful in chronic myeloid leukemia (CML) and long-term survival has become a reality. Despite this outstanding progress, detection of minimal residual disease precludes therapy termination in most TKI-receiving patients.
Delphine Rea +4 more
openaire +3 more sources
Acta medica portuguesa, 2000
The authors describe a clinical case of chronic myeloid leukemia with a typical presentation (massive splenomegaly and marked leucocytosis), but with a complex translocation--t (7; 9; 22) (q11; q34; q11). The evolution was rather atypical with a lymphoblastic crisis in association with osteolytic lesions and with parenchymal and soft tissue ...
I Sousa +4 more
openaire +3 more sources
The authors describe a clinical case of chronic myeloid leukemia with a typical presentation (massive splenomegaly and marked leucocytosis), but with a complex translocation--t (7; 9; 22) (q11; q34; q11). The evolution was rather atypical with a lymphoblastic crisis in association with osteolytic lesions and with parenchymal and soft tissue ...
I Sousa +4 more
openaire +3 more sources
Allografting for chronic myeloid leukemia
Current Opinion in Hematology, 1997Allogeneic stem cell transplantation is the only curative therapy for chronic myeloid leukemia. There have been several recent advances in this field. Early data suggest that blood-derived stem cells are an effective substitute for bone marrow. Allografting can be performed using progenitor cells from other family members, unrelated donors, and ...
John M. Goldman, David G. Savage
openaire +3 more sources